Hunter Syndrome JR-141 Study
Contact
Description
The purpose of this study is to find out if JR-141, an experimental drug, works better than the standard treatment, idursulfase, for MPS II (Hunter Syndrome) and how safe and effective it is in the management of central nervous system symptoms (such as brain or body function loss) and other body symptoms (including lungs, ears, heart, kidneys, and eyes, as well as any type of liver, bone or joint abnormalities) related to MPS II. Since JR-141 is an investigational drug, it has not been approved by the Food and Drug Administration (FDA).
Eligibility and criteria
What to expect
Study participation is divided into 3 different periods:
- Screening Period (up to 4 weeks)
- Treatment Period (104 weeks for Cohort A, 52 weeks for Cohort B)
- Follow up (1 week)
- Cohort A: between 30 months -6 years old
- Cohort B: 6 years or older
Related specialties

We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.